Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Status Terminated

Clinical Trial Summary

This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To achieve an overall response rate of 15% or more.

SECONDARY OBJECTIVES:

I. Determine progression free survival. II. Determine overall survival. III. Evaluate toxicity profile of ABT 869 (linifanib) in this patient population.

OUTLINE:

Patients receive Linifanib orally (PO) once daily (QD). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 3 months for 2 years, and then every 6 months for 3 years. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01365910
Study type	Interventional
Source	Vanderbilt-Ingram Cancer Center
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2011
Completion date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01987726` - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Active, not recruiting	`NCT00826540` - Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	Phase 2
Completed	`NCT00025337` - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated	Phase 3
Recruiting	`NCT04642924` - SGM-101 in Locally Advanced and Recurrent Rectal Cancer	Phase 2/Phase 3
Completed	`NCT01846520` - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers	N/A
Completed	`NCT01217450` - Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors	Phase 1
Completed	`NCT01191684` - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer	Phase 1
Terminated	`NCT01238965` - Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy	Phase 1
Terminated	`NCT01233505` - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT01285102` - Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer	Phase 1
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Completed	`NCT00551421` - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT00407654` - VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer	Phase 2
Completed	`NCT00091182` - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment	Phase 2
Terminated	`NCT00052585` - Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer	Phase 2
Completed	`NCT00023933` - Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer	Phase 1
Not yet recruiting	`NCT05076305` - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Completed	`NCT01740648` - Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	Phase 1
Terminated	`NCT00397878` - AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer	Phase 2
Completed	`NCT00100841` - Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer	Phase 2